Ep. 154 - Madrigal in NASH, Moderna & Neoantigens, the Distillery
BioCentury This Week
English - December 20, 2022 00:00 - 19 minutes - 13.4 MB - ★★★★★ - 11 ratingsScience biotech biopharma pharmaceutical research investment dealmaking Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Ep. 153 - The Inflation Reduction Act
Next Episode: Ep. 155 - U.K. Biotech, Aduhelm, 2022 Approval Trends
Phase III results for resmetirom from Madrigal Pharmaceuticals are more than enough for a regulatory submission in non-alcoholic steatohepatitis, said BioCentury Director of Biopharma Intelligence Paul Bonanos. Bonanos and colleagues discuss what Madrigal got right in running its trial for the challenging NASH indication, and what’s next in the pipeline. BioCentury’s editors also assess highly anticipated, heavily scrutinized data from Moderna among other 4Q22 readouts from neoantigen programs, as well as translational highlights from BioCentury’s Distillery.